Literature DB >> 15930358

Intraprostatic chemotherapy: distribution and transport mechanisms.

M Guillaume Wientjes1, Jenny H Zheng, Leijun Hu, Yuebo Gan, Jessie L-S Au.   

Abstract

PURPOSE: The present study evaluated the tissue distribution and targeting advantage of intraprostatic chemotherapy. EXPERIMENTAL
DESIGN: We studied the delivery and spatial distribution of a fluorescent drug, doxorubicin, in the prostate of beagle dogs, after intraprostatic or i.v. administration. Drug concentrations were measured using high-performance liquid chromatography and confocal fluorescence microscopy.
RESULTS: I.v. and intraprostatic injections yielded qualitatively and quantitatively different doxorubicin distribution in the prostate. A relatively homogeneous distribution was found after i.v. administration, whereas intraprostatic injection yielded a highly heterogeneous distribution with >10-fold higher concentrations localized in a cone-shaped glandular lobule bound by fibromuscular stroma, compared with other parts of the prostate. Compared with i.v. injection, intraprostatic injection yielded, on average, approximately 100-fold higher tissue-to-plasma concentration ratio, ranging from 963-fold near the injection site to 19-fold in the contralateral half of the prostate. The drug distribution within the prostate further suggests an important role for acinar flow in intraprostatic drug transport.
CONCLUSIONS: Intraprostatic administration represents a viable option to deliver high drug concentrations within the prostate. The results further suggest the fibromuscular stroma separating the prostatic lobules as a major barrier to drug transport and convective flow as an important drug transport mechanism in the prostate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930358     DOI: 10.1158/1078-0432.CCR-04-1969

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  Drug delivery systems in urology--getting "smarter".

Authors:  Omid C Farokhzad; Jordan D Dimitrakov; Jeffrey M Karp; Ali Khademhosseini; Michael R Freeman; Robert Langer
Journal:  Urology       Date:  2006-09       Impact factor: 2.649

2.  Intraprostatic ethanol diffusion: comparison of two injection methods using ex vivo human prostates.

Authors:  B J King; T K Mann-Gow; M Kida; M K Plante; S D Perrapato; P Zvara
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-26       Impact factor: 5.554

3.  Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle.

Authors:  Benjamin J King; Mark K Plante; Masatoshi Kida; Travis K Mann-Gow; Rick Odland; Peter Zvara
Journal:  J Urol       Date:  2012-03-16       Impact factor: 7.450

4.  Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems.

Authors:  Twan Lammers; Peter Peschke; Rainer Kühnlein; Vladimir Subr; Karel Ulbrich; Peter Huber; Wim Hennink; Gert Storm
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

5.  The Roles of Tight Junctions and Claudin-1 in the Microbubble-Mediated Ultrasound-Induced Enhancement of Drug Concentrations in Rat Prostate.

Authors:  Yonggang Shang; Xiaoxiao Dong; Guangwei Han; Jia Li; Dong Cui; Chengcheng Liu; Longkun Li; Shanhong Yi
Journal:  J Membr Biol       Date:  2015-08-20       Impact factor: 1.843

6.  Biodegradable intraprostatic doxorubicin implants.

Authors:  Ronnie Ortiz; Jessie L-S Au; Ze Lu; Yuebo Gan; M Guillaume Wientjes
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

7.  Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.

Authors:  Elon C Roti Roti; Scott K Leisman; David H Abbott; Sana M Salih
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

Review 8.  Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.

Authors:  Xiao Hu; Yu-Sen Zhang; Yi-Chao Liu; Na Wang; Xian-Tao Zeng; Ling-Ling Zhang
Journal:  J Nanobiotechnology       Date:  2022-10-04       Impact factor: 9.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.